Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
51 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Gastroenteritis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Gastroenteritis - Pipeline Review, H2 2014', provides an overview of the Gastroenteritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gastroenteritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastroenteritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastroenteritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gastroenteritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastroenteritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gastroenteritis Overview 6 Therapeutics Development 7 Pipeline Products for Gastroenteritis - Overview 7 Pipeline Products for Gastroenteritis - Comparative Analysis 8 Gastroenteritis - Therapeutics under Development by Companies 9 Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 10 Gastroenteritis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Gastroenteritis - Products under Development by Companies 14 Gastroenteritis - Products under Investigation by Universities/Institutes 15 Gastroenteritis - Companies Involved in Therapeutics Development 16 Bharat Biotech International Limited 16 Cocrystal Pharma, Inc. 17 RedHill Biopharma Ltd. 18 Takeda Pharmaceutical Company Limited 19 UMN Pharma Inc. 20 Gastroenteritis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 norovirus (bivalent) vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ondansetron hydrochloride CR - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ORV-116E - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Inhibit RNA Dependent RNA Polymerase for Acute Gastroenteritis - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 UMN-2002 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 UMN-2003 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Gastroenteritis - Recent Pipeline Updates 38 Gastroenteritis - Product Development Milestones 43 Featured News & Press Releases 43 Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 43 Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 44 Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 45 Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 46 Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 51 Disclaimer 51
List of Tables Number of Products under Development for Gastroenteritis, H2 2014 7 Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Gastroenteritis - Pipeline by Bharat Biotech International Limited, H2 2014 16 Gastroenteritis - Pipeline by Cocrystal Pharma, Inc., H2 2014 17 Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2014 18 Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 19 Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Gastroenteritis Therapeutics - Recent Pipeline Updates, H2 2014 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.